Adults 25 to 85, any sex, with Parkinson Disease. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Change in Unified Parkinson's Disease Rating Scale (UPDRS Part III Motor Examination) During "OFF" Time From Baseline to the End of Double-Blind Maintenance PeriodPrimary· From Baseline (Week 0) to end of Maintenance Period (up to 54 weeks)
The UPDRS Part III (motor symptoms sub-scale) Assessment consists of 17 items, measured on a 5-Point scale (0-Normal to 4-Severe), addressing speech, facial expression, tremor at rest, action tremor, rigidity, finger taps, hand movements, hand pronation and supination, leg agility, arising from chair, posture, gait, postural stability, and body bradykinesia. The participant's score is calculated as a sum of the scores of the 17 individual questions. This sum score ranges from 0 to 108. Higher scores denote greater disability.
A participant has been considered "OFF" when he/she has been off L-
Group
Value
95% CI
Full Analysis Set (Liraglutide-treated Subjects)
-2.3
± 9.4
Full Analysis Set (Placebo-treated Subjects)
-5.0
± 7.1
Change in the Non-Motor Symptoms Scale (NMSS) Total Score From Baseline to the End of the Double-Blind Maintenance PeriodPrimary· From Baseline (Week 0) to the End of Maintenance Period (up to Week 54)
The NMSS is a 30-item rater-based scale to assess a wide range of non-motor symptoms in patients with Parkinson's disease. The NMSS measures severity and frequency of non-motor symptoms across nine dimensions (cardiovascular, sleep/fatigue, mood/apathy, perceptual problems/hallucinations, attention/memory, gastrointestinal, urinary, sexual function, and miscellaneous which includes pain, taste/smell, weight change, and excessive sweating). Higher scores indicate a higher burden of these symptoms on the patient.
There are 30 items to be scored, and the item scores are calculated as the product
Group
Value
95% CI
Full Analysis Set (Liraglutide-treated Subjects)
-5.5
± 25.3
Full Analysis Set (Placebo-treated Subjects)
6.5
± 21.3
Change in the Mattis Dementia Rating Scale (DRS-2) From Baseline to the End of Double-Blind Maintenance PeriodPrimary· From Baseline (Week 0) to the end of Maintenance Period (up to 54 weeks)
The DRS-2 assesses individuals in five areas resulting in five sub-scale scores. These scores are used to determine the overall score and level of cognitive functioning ability. The five areas include:
Attention - measured using eight items Construction - measured using six items Conceptualization - measured using six items Initiation/Preservation - measured using eleven items Memory - measured using five items Higher raw scores indicate better cognitive status, with scores ranging from 0 to 144. Normative data in healthy subjects range from 137 to 144.
Group
Value
95% CI
Full Analysis Set (Liraglutide-treated Subjects)
1.4
± 9.3
Full Analysis Set (Placebo-treated Subjects)
-0.3
± 9.1
Change in the Homeostasis Model Assessment of Insulin Resistance (HOMA-IR) Index From Baseline to the End of Maintenance PeriodSecondary· From Baseline (Week 0) to end of Maintenance Period (up to 54 weeks)
Peripheral insulin resistance was assessed using the Homeostasis Model Assessment of Insulin Resistance (HOMA-IR) Index. The HOMA-IR tool is a validated, non-invasive tool to assess the relationship between glucose and insulin. A score less than 1 means indicates insulin-sensitivity (Optimal). Greater than 1.9 indicates early insulin resistance, and a score greater than 2.9 indicates significant insulin resistance.
An increase in one's HOMA-IR score may indicate increased insulin resistance.
Group
Value
95% CI
Full Analysis Set (Liraglutide-treated Subjects)
0.1
± 1.1
Full Analysis Set (Placebo-treated Subjects)
0.3
± 0.8
Change in the Unified Parkinson's Disease Rating Scale Total Score From Baseline to the End of Double-Blind Maintenance PeriodSecondary· From Baseline (Week 0) to end of Maintenance Period (up to 54 weeks)
Total UPDRS Score (Parts I, II, III, and IV; administered in the ON condition) Change from Baseline to End of Maintenance Period.
UPDRS I evaluation of mentation, behavior, and mood UPDRS II self-evaluation of the activities of daily life (ADLs) including speech, swallowing, handwriting, dressing, hygiene, falling, salivating, turning in bed, walking, and cutting food UPDRS III clinician-scored monitored motor evaluation UPDRS IV evaluation of complications in therapy and motor fluctuations, including OFF time and dyskinesia
The UPDRS I, II, III, and IV scores and subscores are calculated as
Group
Value
95% CI
Full Analysis Set (Liraglutide-treated Subjects)
-4.9
± 12.7
Full Analysis Set (Placebo-treated Subjects)
2.3
± 10.4
Change in The Parkinson's Disease Questionnaire (PDQ-39) From Baseline to the End of Double-Blind Maintenance PeriodSecondary· From Baseline (Week 0) to end of Maintenance Period (up to 54 weeks)
The Parkinson's Disease Questionnaire (PDQ-39) is a 39-item patient-reported rating scale that measures Parkinson's disease-specific health related quality of life.
It covers 8 areas: mobility, activities of daily living (ADL), emotional well-being, stigma, social support, cognition, communication and bodily discomfort.
Lower scores indicate better health related quality of life. PDQ-39 total scores range from 0 to 800. The total score can be summarised into the PDQ-39 summary index score (range of scores 0 to 100). A mean change in the PDQ-39 summary index score of about 1.6 points relates
Group
Value
95% CI
Full Analysis Set (Liraglutide-treated Subjects)
-2.5
± 9.9
Full Analysis Set (Placebo-treated Subjects)
11.2
± 14.0
Adverse events — posted to ClinicalTrials.gov
Time frame: Adverse Event collection commenced upon signing of consent at Screening and occurred at Baseline Week 1, Week 2, Week 6, Week 14, Week 28, Week 38, Week 54, and at follow-up Week 58..
Reporting threshold: 5%.
Adverse-event reports describe events observed during the trial — not all are caused by the drug.
NCT07225816 — Examination of How the Duration of Fasting and Temporary Stopping of GLP-1 Medications Affect the Amount of Food Left in
· Phase 1
· recruiting
NCT06818292 — Investigation of the Relationship Between Peripheral and Central Metabolic Changes Induced by GLP-1 Agonists
· NA
· completed
NCT06283641 — Study to Evaluate the Safety and Effectiveness of Saxenda® for Weight Management in Routine Clinical Practice in Taiwan.
· completed
NCT06501326 — Efficacy and Safety of Liraglutide in the Treatment of Obesity Combined With Metabolism Associated Fatty Liver Disease
· Phase 4
· unknown
NCT05756764 — Anti-obesity Pharmacotherapy and Inflammation
· active not recruiting
Other recruiting trials for Parkinson Disease
Currently open trials in the same condition.
NCT07399496 — Accelerated TMS for Apathy in PD
· NA
· recruiting
NCT07371338 — Phase 1 Clinical Trial to Evaluate the Safety, Efficacy, and Pharmacokinetics of IPS101A in Parkinson's Disease Patients
· Phase 1
· recruiting
NCT07442370 — The Effect of Functional Rotational Exercises on Fall Risk and Mobility in Parkinson's Disease Patients
· NA
· recruiting
NCT06848205 — Percept Transitions in FOG and PD
· NA
· recruiting
NCT07432958 — A Study to Evaluate the Effectiveness of Two Doses of AP-472 as Adjunctive Therapy to Levodopa in Parkinson's Disease (P
· Phase 2
· recruiting
Other Cedars-Sinai Medical Center trials
Trials by the same sponsor.
NCT06012487 — Correlates and Control of Blood Pressure Variability
· Phase 1
· not yet recruiting
NCT07495995 — SAMe for Prevention of Liver Cancer in MASLD-Related Cirrhosis
· Phase 2
· not yet recruiting
NCT07413965 — TAVR vs SAVR in Severe Bicuspid Aortic Stenosis
· NA
· not yet recruiting
NCT06521021 — CHOICE to AVOID or RESIST
· NA
· not yet recruiting
NCT07499089 — Together-Breast Cancer Support Platform
· not yet recruiting
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Cedars-Sinai Medical Center
Last refreshed: 7 March 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02953665.